{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:55:18Z","timestamp":1772254518813,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Xi\u2019an Janssen Pharmaceutical Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40263-023-01056-x","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T15:02:22Z","timestamp":1704726142000},"page":"55-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0404-5500","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7111-8514","authenticated-orcid":false,"given":"Chong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"1056_CR1","doi-asserted-by":"publisher","DOI":"10.1270\/P6-57","author":"CS Haller","year":"2014","unstructured":"Haller CS, Padmanabhan JL, Lizano P, Torous J, Keshavan M. Recent advances in understanding schizophrenia. F1000prime Reports. 2014. https:\/\/doi.org\/10.1270\/P6-57.","journal-title":"F1000prime Reports"},{"issue":"14","key":"1056_CR2","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1017\/S0033291714000610","volume":"44","author":"M Harrow","year":"2014","unstructured":"Harrow M, Jobe T, Faull R. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med. 2014;44(14):3007\u201316. https:\/\/doi.org\/10.1017\/S0033291714000610.","journal-title":"Psychol Med"},{"issue":"6","key":"1056_CR3","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","volume":"39","author":"E J\u00e4\u00e4skel\u00e4inen","year":"2013","unstructured":"J\u00e4\u00e4skel\u00e4inen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296\u2013306. https:\/\/doi.org\/10.1093\/schbul\/sbs130.","journal-title":"Schizophr Bull"},{"issue":"1\u20133","key":"1056_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2013.05.016","volume":"148","author":"R Emsley","year":"2013","unstructured":"Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 2013;148(1\u20133):117\u201321. https:\/\/doi.org\/10.1016\/j.schres.2013.05.016.","journal-title":"Schizophr Res"},{"issue":"7","key":"1056_CR5","doi-asserted-by":"publisher","first-page":"990","DOI":"10.4088\/JCP.08m04221","volume":"70","author":"J-P Lindenmayer","year":"2009","unstructured":"Lindenmayer J-P, Liu-Seifert H, Kulkarni PM, Kinon BJ, Stauffer V, Edwards SE, et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry. 2009;70(7):990. https:\/\/doi.org\/10.4088\/JCP.08m04221.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1056_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","volume":"56","author":"D Robinson","year":"1999","unstructured":"Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241\u20137. https:\/\/doi.org\/10.1001\/archpsyc.56.3.241.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"1056_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3109\/13651501.2016.1149195","volume":"20","author":"S Porcelli","year":"2016","unstructured":"Porcelli S, Bianchini O, De Girolamo G, Aguglia E, Crea L, Serretti A. Clinical factors related to schizophrenia relapse. Int J Psychiatry Clin Pract. 2016;20(2):54\u201369. https:\/\/doi.org\/10.3109\/13651501.2016.1149195.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"6","key":"1056_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1176\/appi.ajp.2009.09030358","volume":"167","author":"C-Y Wang","year":"2010","unstructured":"Wang C-Y, Xiang Y-T, Cai Z-J, Weng Y-Z, Bo Q-J, Zhao J-P, et al. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry. 2010;167(6):676\u201385. https:\/\/doi.org\/10.1176\/appi.ajp.2009.09030358.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"1056_CR9","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1176\/appi.ajp.159.10.1653","volume":"159","author":"A Zygmunt","year":"2002","unstructured":"Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry. 2002;159(10):1653\u201364. https:\/\/doi.org\/10.1176\/appi.ajp.159.10.1653.","journal-title":"Am J Psychiatry"},{"key":"1056_CR10","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.13033","volume":"10","author":"Y Long","year":"2022","unstructured":"Long Y, Tong X, Awad M, Xi S, Yu Y. Violence, runaway, and suicide attempts among people living with schizophrenia in China: prevalence and correlates. PeerJ. 2022;10: e13033. https:\/\/doi.org\/10.7717\/peerj.13033.","journal-title":"PeerJ"},{"issue":"suppl 1","key":"1056_CR11","first-page":"49","volume":"28","author":"J Pecenak","year":"2007","unstructured":"Pecenak J. Relapse prevention in schizophrenia: evidence from longterm, randomized, double-blind clinical trials. Neuro Endocrinol Lett. 2007;28(suppl 1):49\u201370.","journal-title":"Neuro Endocrinol Lett"},{"issue":"10","key":"1056_CR12","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1185\/030079907X226050","volume":"23","author":"SX Sun","year":"2007","unstructured":"Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007;23(10):2305\u201312. https:\/\/doi.org\/10.1185\/030079907X226050.","journal-title":"Curr Med Res Opin"},{"key":"1056_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2147\/PPA.S41609","volume":"7","author":"T Dilla","year":"2013","unstructured":"Dilla T, Ciudad A, Alvarez M. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence. 2013;7:275. https:\/\/doi.org\/10.2147\/PPA.S41609.","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"1056_CR14","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868\u201372. https:\/\/doi.org\/10.1176\/appi.ajp.2020.177901.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1056_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/inm.12964","volume":"31","author":"CT Okoli","year":"2022","unstructured":"Okoli CT, Kappi A, Wang T, Makowski A, Cooley AT. The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: a systematic review and meta-analysis. Int J Ment Health Nurs. 2022;31(3):469\u2013535. https:\/\/doi.org\/10.1111\/inm.12964.","journal-title":"Int J Ment Health Nurs"},{"issue":"5","key":"1056_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387\u2013404. https:\/\/doi.org\/10.1016\/s2215-0366(21)00039-0.","journal-title":"Lancet Psychiatry"},{"key":"1056_CR17","unstructured":"2012 China Drug Evaluation report: Center for Drug Evaluation, NMPA; 2013. Available from: https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/a28681d04382f4546668447fdaba90dd."},{"issue":"4","key":"1056_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40263-017-0416-1","volume":"31","author":"MO Magnusson","year":"2017","unstructured":"Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, et al. Dosing and switching strategies for paliperidone palmitate 3-month formulation in patients with schizophrenia based on population pharmacokinetic modeling and simulation, and clinical trial data. CNS Drugs. 2017;31(4):273\u201388. https:\/\/doi.org\/10.1007\/s40263-017-0416-1.","journal-title":"CNS Drugs"},{"key":"1056_CR19","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2147\/NDT.S81760","volume":"11","author":"T Si","year":"2015","unstructured":"Si T, Zhang K, Tang J, Fang M, Li K, Zhuo J, et al. Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study. Neuropsychiatr Dis Treat. 2015;11:1483. https:\/\/doi.org\/10.2147\/NDT.S81760.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1\u20133","key":"1056_CR20","first-page":"36","volume":"17","author":"T Ohnishi","year":"2020","unstructured":"Ohnishi T, Kobayashi H, Yamaoka T, Toma T, Imai K, Wakamatsu A, et al. The effects of paliperidone palmitate 1 month on the employment status and social functioning of patients with schizophrenia. Innov Clin Neurosci. 2020;17(1\u20133):36.","journal-title":"Innov Clin Neurosci"},{"issue":"9","key":"1056_CR21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/02698811211009794","volume":"35","author":"P Wallman","year":"2021","unstructured":"Wallman P, Clark I, Taylor D. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: two year follow-up of use in clinical practice. J Psychopharmacol. 2021;35(9):1091\u20138. https:\/\/doi.org\/10.1177\/02698811211009794.","journal-title":"J Psychopharmacol"},{"issue":"8","key":"1056_CR22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","volume":"72","author":"J Berwaerts","year":"2015","unstructured":"Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiat. 2015;72(8):830\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0241.","journal-title":"JAMA Psychiat"},{"issue":"7","key":"1056_CR23","doi-asserted-by":"publisher","first-page":"pyw018","DOI":"10.1093\/ijnp\/pyw018","volume":"19","author":"AJ Savitz","year":"2016","unstructured":"Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016;19(7):pyw018. https:\/\/doi.org\/10.1093\/ijnp\/pyw018.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1056_CR24","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.2147\/ppa.S322880","volume":"15","author":"G Li","year":"2021","unstructured":"Li G, Keenan A, Daskiran M, Mathews M, Nuamah I, Orman C, et al. Relapse and Treatment adherence in patients with schizophrenia switching from paliperidone palmitate once-monthly to three-monthly formulation: a retrospective health claims database analysis. Patient Prefer Adherence. 2021;15:2239\u201348. https:\/\/doi.org\/10.2147\/ppa.S322880.","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"1056_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40263-021-00838-5","volume":"35","author":"K-C Yang","year":"2021","unstructured":"Yang K-C, Liao Y-T, Yang Y-K, Lin S-K, Liang C-S, Bai Y-M. Evidence-based expert consensus regarding long-acting injectable antipsychotics for schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN). CNS Drugs. 2021;35(8):893\u2013905. https:\/\/doi.org\/10.1007\/s40263-021-00838-5.","journal-title":"CNS Drugs"},{"issue":"11","key":"1056_CR26","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1185\/03007995.2015.1085849","volume":"31","author":"S Gopal","year":"2015","unstructured":"Gopal S, Vermeulen A, Nandy P, Ravenstijn P, Nuamah I, Buron Vidal JA, et al. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Curr Med Res Opin. 2015;31(11):2043\u201354. https:\/\/doi.org\/10.1185\/03007995.2015.1085849.","journal-title":"Curr Med Res Opin."},{"key":"1056_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/NDT.S278298","volume":"17","author":"A O\u2019Donnell","year":"2021","unstructured":"O\u2019Donnell A, Rao S, Turkoz I, Gopal S, Kim E. Defining, \u201cadequately treated\u201d: a post hoc analysis examining characteristics of patients with schizophrenia successfully transitioned from once-monthly paliperidone palmitate to once-every-3-months paliperidone palmitate. Neuropsychiatr Dis Treat. 2021;17:1. https:\/\/doi.org\/10.2147\/NDT.S278298.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1056_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.psychres.2019.02.036","volume":"274","author":"TM Si","year":"2019","unstructured":"Si TM, Long Zhang Y, Feng Y, Zhuo JM, Cai S, Zhang L. Association between symptom control and functional improvement in patients with acute schizophrenia: a post hoc analysis of an open-label, single-arm, multi-center study of paliperidone-extended release formulation. Psychiatry Res. 2019;274:301\u20135. https:\/\/doi.org\/10.1016\/j.psychres.2019.02.036.","journal-title":"Psychiatry Res"},{"key":"1056_CR29","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2147\/NDT.S294503","volume":"17","author":"T Ohnishi","year":"2021","unstructured":"Ohnishi T, Wakamatsu A, Kobayashi H. Early improvement of psychiatric symptoms with long-acting injectable antipsychotic predicts subsequent social functional remission in patients with schizophrenia. Neuropsychiatr Dis Treat. 2021;17:1095. https:\/\/doi.org\/10.2147\/NDT.S294503.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1056_CR30","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2147\/ndt.S373725","volume":"18","author":"I Turkoz","year":"2022","unstructured":"Turkoz I, Daskiran M, Starr HL, Najarian D, Lopena O, Obando C, et al. Comparing relapse rates in real-world patients with schizophrenia who were adequately versus not adequately treated with paliperidone palmitate once-monthly injections before transitioning to once-every-3-months injections. Neuropsychiatric Dis Treat. 2022;18:1927\u201337. https:\/\/doi.org\/10.2147\/ndt.S373725.","journal-title":"Neuropsychiatric Dis Treat"},{"issue":"2","key":"1056_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376. https:\/\/doi.org\/10.1093\/schbul\/13.2.261.","journal-title":"Schizophr Bull"},{"issue":"2","key":"1056_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.psychres.2007.11.012","volume":"161","author":"H Nasrallah","year":"2008","unstructured":"Nasrallah H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the personal and social performance scale in patients with stable schizophrenia. Psychiatry Res. 2008;161(2):213\u201324. https:\/\/doi.org\/10.1016\/j.psychres.2007.11.012.","journal-title":"Psychiatry Res"},{"issue":"6","key":"1056_CR33","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1365-2753.2007.00921.x","volume":"14","author":"M Berk","year":"2008","unstructured":"Berk M, Ng F, Dodd S, Callaly T, Campbell S, Bernardo M, et al. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. J Eval Clin Pract. 2008;14(6):979\u201383. https:\/\/doi.org\/10.1111\/j.1365-2753.2007.00921.x.","journal-title":"J Eval Clin Pract"},{"key":"1056_CR34","doi-asserted-by":"publisher","DOI":"10.2307\/1907187","author":"HB Mann","year":"1945","unstructured":"Mann HB. Nonparametric tests against trend. Econometrica. 1945. https:\/\/doi.org\/10.2307\/1907187.","journal-title":"Econometrica"},{"issue":"11","key":"1056_CR35","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.4088\/jcp.v67n1104","volume":"67","author":"M Lambert","year":"2006","unstructured":"Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67(11):1690\u20137. https:\/\/doi.org\/10.4088\/jcp.v67n1104.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1056_CR36","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.eurpsy.2009.09.001","volume":"25","author":"M Lambert","year":"2010","unstructured":"Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry. 2010;25(4):220\u20139. https:\/\/doi.org\/10.1016\/j.eurpsy.2009.09.001.","journal-title":"Eur Psychiatry"},{"key":"1056_CR37","doi-asserted-by":"publisher","DOI":"10.3188\/DCNS.2010.12.3\/mlambert","author":"M Lambert","year":"2022","unstructured":"Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients\u2019 perspective 5 years later. Dialogues Clin Neurosci. 2022. https:\/\/doi.org\/10.3188\/DCNS.2010.12.3\/mlambert.","journal-title":"Dialogues Clin Neurosci"},{"key":"1056_CR38","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2147\/NDT.S158353","volume":"14","author":"N Li","year":"2018","unstructured":"Li N, Feng Y, Lu H, Cai SL, Zhuo J, Si T, et al. Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics. Neuropsychiatr Dis Treat. 2018;14:825. https:\/\/doi.org\/10.2147\/NDT.S158353.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1056_CR39","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2147\/NDT.S194264","volume":"15","author":"AI Nash","year":"2019","unstructured":"Nash AI, Turkoz I, Savitz AJ, Mathews M, Kim E. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation. Neuropsychiatr Dis Treat. 2019;15:731. https:\/\/doi.org\/10.2147\/NDT.S194264.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"7","key":"1056_CR40","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28.","journal-title":"Psychiatry (Edgmont)"},{"issue":"1\u20133","key":"1056_CR41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.schres.2007.09.006","volume":"98","author":"SZ Levine","year":"2008","unstructured":"Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res. 2008;98(1\u20133):318\u201322. https:\/\/doi.org\/10.1016\/j.schres.2007.09.006.","journal-title":"Schizophr Res"},{"issue":"S52","key":"1056_CR42","doi-asserted-by":"publisher","first-page":"s63","DOI":"10.1192\/bjp.195.52.s63","volume":"195","author":"JM Kane","year":"2009","unstructured":"Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry. 2009;195(S52):s63\u20137. https:\/\/doi.org\/10.1192\/bjp.195.52.s63.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"1056_CR43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1176\/appi.ps.201500056","volume":"67","author":"X Wang","year":"2016","unstructured":"Wang X, Zhang W, Ma N, Guan L, Law SF, Yu X, et al. Adherence to antipsychotic medication by community-based patients with schizophrenia in China: a cross-sectional study. Psychiatric Services (Washington, DC). 2016;67(4):431\u20137. https:\/\/doi.org\/10.1176\/appi.ps.201500056.","journal-title":"Psychiatric Services (Washington, DC)"},{"key":"1056_CR44","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.2147\/NDT.S134287","volume":"13","author":"AJ Savitz","year":"2017","unstructured":"Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, et al. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study. Neuropsychiatr Dis Treat. 2017;13:2193. https:\/\/doi.org\/10.2147\/NDT.S134287.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"1056_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12393","volume":"12","author":"CT Tang","year":"2020","unstructured":"Tang CT, Chua EC, Chew QH, He YL, Si TM, Chiu HFK, et al. Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region. Asia Pac Psychiatry. 2020;12(4): e12393. https:\/\/doi.org\/10.1111\/appy.12393.","journal-title":"Asia Pac Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01056-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01056-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01056-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T17:50:37Z","timestamp":1706205037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01056-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01056-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"20 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Xi\u2019an Janssen Pharmaceutical Ltd. Xi\u2019an Janssen Pharmaceutical Ltd. participated in the study design, data extraction, analysis, and interpretation of the analytical results, and the writing of the manuscript, and was involved in the decision and approval to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gang Wang reports receiving grants outside of the submitted work from Xi'an Janssen, Eli Lily, GlaxoSmithKline, Dainippon Sumitomo Pharma, Otsuka Pharmaceutical, and ShiJiaZhuang No 4 Pharm. Shandong Luye, Chiatai Tianqing, and Jiangsu Hansoh. Xin Li, Chong Ye, Wangyi Zhang, and Miaomiao Jia are employees of Xi\u2019an Janssen Pharmaceutical Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at . As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access [YODA] Project site at .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"This study was approved by Ethics Committee or Institutional Review Board of the following institutions (see Online Resource 1 for detailed information): Beijing Anding Hospital, Capital Medical University; Peking University Six Hospital; Shanghai Mental Health Center; Guangzhou Brain Hospital; The Third Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Kunshan Medical University; Renmin Hospital of Wuhan University; Beijing Huilongguan Hospital; The Second People\u2019s Hospital, Hunan Province; Xi\u2019an Mental Health Center; The First Affiliated of Fourth Military Medical University; Tianjin Anding Hospital; The Second Affiliated Hospital of Zhejiang University School of Medicine; Zhejiang University School of Medicine; The Institution of the Mental Health Center of Hebei Province; Guangdong Provincial People\u2019s Hospital.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent was obtained from all patients before enrollment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed substantially to the study design, analysis, and interpretation of the data and final approval of the manuscript. X.L. and G.W. designed the study. C.Y. performed the statistical analysis. X.L. and C.Y. wrote the first draft of the manuscript. G.W., W.Z., and M.J. reviewed and edited the manuscript. All authors agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s Contributions"}}]}}